Our Strategy

We plan to continue to expand our Impax Generics division by targeting complex solid oral and alternative dosage form Abbreviated New Drug Applications (ANDAs) with high revenue potential, including products with the potential to be first-to-file or first-to-market. Our products and product candidates are generally difficult to formulate and manufacture, providing certain competitive advantages. In addition to our product pipeline of more than 20 pending applications at the FDA and a number of products in various stages of development for which applications have not yet been filed.

A core component of our strategy includes an ongoing focus in our Impax Specialty Pharma division on proprietary brand-name pharmaceutical products to treat CNS disorders and other specialty segments. We believe that we have the research, development and formulation expertise to develop branded products that will deliver significant improvements over existing therapies. We plan to continue investing in our development pipeline, both internally and through acquisitions and partnerships primarily focused on late-stage and next generation product opportunities.

The Company’s leading brand R&D product is IPX203, a new extended-release oral capsule formulation of carbidopa and levodopa (CD-LD), as a potential treatment for symptoms of Parkinson’s disease. The Company is currently enrolling study centers from the completed single dose study to a Phase 2b multiple dose study of IPX203 in patients with advanced Parkinson’s disease.